SeaStar Medical Holding Corp's stock experienced a notable increase of nearly 10% in after-hours trading following the appointment of Michael Messinger as Chief Financial Officer. This leadership change has boosted investor confidence in the company's future prospects.
In addition to the leadership update, SeaStar Medical is preparing to present at the NobleCon21 Investor Conference on December 3, 2025. The presentation will cover the company's therapeutic platform and financial positioning, which may further attract investor interest.
The stock's rise aligns with broader market trends, as the Nasdaq-100 and S&P 500 also posted gains. This suggests that while the CFO appointment is a significant factor, overall market sentiment is contributing to the positive movement in SeaStar Medical's stock.
Wall Street analysts forecast ICU stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for ICU is 1.00 USD with a low forecast of 1.00 USD and a high forecast of 1.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
Wall Street analysts forecast ICU stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for ICU is 1.00 USD with a low forecast of 1.00 USD and a high forecast of 1.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 2.335
Low
1.00
Averages
1.00
High
1.00
Current: 2.335
Low
1.00
Averages
1.00
High
1.00
No data
About ICU
SeaStar Medical Holding Corporation is a commercial-stage medical technology company, which is focused on transforming treatments for critically ill patients facing organ failure and potential loss of life. The Company’s Selective Cytopheretic Device (SCD) is designed as a disease-modifying device that neutralizes over-active immune cells and stops the cytokine storm that yields destructive hyperinflammation and creates a cascade of events that wreak havoc in the patient’s body. It has broad potential applications for patients suffering from both acute and chronic kidney disease as well as cardiovascular and other serious inflammatory diseases. Its SCD therapy is an extracorporeal synthetic membrane device designed to bind activated leukocytes (neutrophils and monocytes) when integrated into an existing continuous renal replacement therapy (CRRT) circuit in conjunction with the use of regional citrate anticoagulation (RCA).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
